Phase I study of zactima (ZD6474) [vandetanib] plus imatinib mesylate and hydroxyurea [hydroxycarbamide] for patients with recurrent malignant glioma.
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2012
At a glance
- Drugs Vandetanib (Primary) ; Hydroxycarbamide; Imatinib
- Indications Glioma
- Focus Adverse reactions
- 10 Aug 2012 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 11 Oct 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record